ArticleMMWR. Morbidity and mortality weekly report2020
Update on Extensively Drug-Resistant Salmonella Serotype Typhi Infections Among Travelers to or from Pakistan and Report of Ceftriaxone-Resistant Salmonella Serotype Typhi Infections Among Travelers to Iraq - United States, 2018-2019.
Article in MMWR. Morbidity and mortality weekly report, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Pooled it
- Typhoid Fever in the Eastern Mediterranean Region: A Systematic Review, 1990-2021.The American journal of tropical medicine and hygiene · 2023Pooled it
- Azithromycin-resistantJAC-antimicrobial resistance · 2026Article
- Review
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- The TyphiNET data visualisation dashboard: unlocking Salmonella Typhi genomics data to support public health.Genome medicine · 2025Article
- Current Antimicrobial Susceptibility Trends and Clinical Outcomes of TyphoidalTropical medicine and infectious disease · 2025Article
- Exogenous cystine increases susceptibility of drug-resistantFrontiers in microbiology · 2025Article
- Foodborne Infections andVaccines · 2024Review
- Antimicrobial Resistance Associated with Mass Gatherings: A Systematic Review.Tropical medicine and infectious disease · 2024Review
- Article
- Navigating the network: a narrative overview of AMR surveillance and data flow in the United States.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Epidemiology of Multidrug-ResistantJournal of tropical medicine · 2024Article
- Zingerone inhibits biofilm formation and enhances antibiotic efficacy against Salmonella biofilm.World journal of microbiology & biotechnology · 2023Article
- Typhoid Control in an Era of Antimicrobial Resistance: Challenges and Opportunities.Open forum infectious diseases · 2023Article
- Human Salmonellosis: A Continuous Global Threat in the Farm-to-Fork Food Safety Continuum.Foods (Basel, Switzerland) · 2023Review
- Genomic Investigation ofMicroorganisms · 2023Article
- A Ten-Year Retrospective Survey of Antimicrobial Susceptibility Patterns among Salmonella enterica subsp.Microbiology spectrum · 2023Article
- Molecular Characterization of Extensively Drug ResistantInfection and drug resistance · 2023Article
- Characterization of a P1-bacteriophage-like plasmid (phage-plasmid) harbouringMicrobial genomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftriaxone-resistant Salmonella enterica serotype Typhi (Typhi), the bacterium that causes typhoid fever, is a growing public health threat. Extensively drug-resistant (XDR) Typhi is resistant to ceftriaxone and other antibiotics used for treatment, including ampicillin, chloramphenicol, ciprofloxacin, and trimethoprim-sulfamethoxazole (1). In March 2018, CDC began enhanced surveillance for ceftriaxone-resistant Typhi in response to an ongoing outbreak of XDR typhoid fever in Pakistan. CDC had previously reported the first five cases of XDR Typhi in the United States among patients who had spent time in Pakistan (2). These illnesses represented the first cases of ceftriaxone-resistant Typhi documented in the United States (3). This report provides an update on U.S. cases of XDR typhoid fever linked to Pakistan and describes a new, unrelated cluster of ceftriaxone-resistant Typhi infections linked to Iraq. Travelers to areas with endemic Typhi should receive typhoid vaccination before traveling and adhere to safe food and water precautions (4). Treatment of patients with typhoid fever should be guided by antimicrobial susceptibility testing whenever possible (5), and clinicians should consider travel history when selecting empiric therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.